Status:
COMPLETED
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Lead Sponsor:
vTv Therapeutics
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receiv...
Eligibility Criteria
Inclusion
- Be male or female, aged 18 through 75 years at screening.
- Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)
- On a stable dose of background medication for the treatment of diabetes
- Body Mass Index (BMI) between 20-40 kg/m2 (inclusive)
Exclusion
- Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT01474083
Start Date
November 1 2011
End Date
September 1 2012
Last Update
September 13 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site 009
Little Rock, Arkansas, United States, 72211
2
Forest Investigative Site 006
Chula Vista, California, United States, 91911
3
Forest Investigative Site 002
DeLand, Florida, United States, 32720
4
Forest Investigative Site 001
Miami, Florida, United States, 33014